文献速递头痛与眩晕

慢性偏头痛患者在接受CGRP或其受体单克隆抗体治疗前后的血清α和β-CGRP水平

Serum Alpha and Beta-CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor.
PubMed 文献 · Ann Neurol · 2023-04-21

研究纳入103例开始单克隆抗体治疗的慢性偏头痛患者和78例年龄性别匹配的健康对照,检测基线、首次给药后2周和3个月的血清α与β-CGRP水平,发现基线α-CGRP在患者中显著升高且随治疗显著下降,下降幅度与每月头痛天数减少正相关,β-CGRP无差异且未受治疗调节。

要点

  • 慢性偏头痛患者基线α-CGRP中位数50.3 pg/ml,显著高于健康对照的37.5 pg/ml。
  • 单克隆抗体治疗后α-CGRP显著下降,2周和3个月中位数分别为40.4和40.9 pg/ml。
  • α-CGRP绝对下降与每月头痛天数减少正相关,β-CGRP在患者与对照间无差异且未受治疗调节。

核心结论

  • 无论靶向CGRP还是其受体,单克隆抗体治疗均能使慢性偏头痛患者基线升高的α-CGRP水平逐渐正常化,且该效应与疗效指标相关,支持该神经肽作为首个慢性偏头痛生物标志物。

研究设计与样本

  • 研究纳入开始单克隆抗体治疗的慢性偏头痛患者,并与性别和年龄匹配的健康对照配对。
  • 在首次单克隆抗体剂量前、后2周(M0.5)和3个月(M3)采血,均在无偏头痛发作期,健康对照采血一次。
  • 采用针对每种亚型特异的酶联免疫吸附试验(ELISA)测量α和β-CGRP血清水平。

主要发现

  • 基线α-CGRP水平在103例慢性偏头痛患者中显著升高(中位数=50.3,95%CI=40.5-57.0 pg/ml), compared to 78例健康对照(中位数=37.5,95%CI=33.9-45.0 pg/ml;差值95%CI=2.85-17.08 pg/ml)。
  • 单克隆抗体治疗过程中α-CGRP显著下降(n=96;M0.5:中位数=40.4,95%CI=35.6-48.2 pg/ml;M3:中位数=40.9,95%CI=36.3-45.9 pg/ml)。
  • α-CGRP在整个治疗期间的绝对下降与每月头痛天数(MMDs)减少正相关。
  • α-CGRP的负向调节与患者整体印象变化量表(PGIC)阳性评分显著相关,并与镇痛药过度使用逆转相关。
  • β-CGRP在慢性偏头痛患者(中位数=4.2,95%CI=3.0-4.8 pg/ml)与健康对照(中位数=4.4,95%CI=3.4-5.6 pg/ml;差值95%CI=-1.09至0.60)间基线无差异,且未受单克隆抗体治疗调节(n=96;M0.5:中位数=4.5,95%CI=3.5-5.2 pg/ml;M3:中位数=4.6,95%CI=3.7-5.2 pg/ml)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to analyze the evolution of alpha and beta-CGRP circulating levels throughout CGRP monoclonal antibodies (mAbs) treatment in patients with chronic migraine (CM). METHODS: We recruited patients with CM beginning mAbs along with sex and age paired healthy controls (HCs). Blood was extracted before, 2 weeks (M0.5) and 3 months (M3) after the first dose of mAbs, always in free-migraine periods, and once for HCs. Alpha and beta-CGRP serum levels were measured using enzyme-linked immunosorbent assays (ELISAs) specific for each isoform. RESULTS: Baseline alpha-CGRP levels were significantly elevated in 103 patients with CM (median = 50.3, 95% confidence interval [CI] = 40.5-57.0 pg/ml) compared to 78 HCs (median = 37.5, 95% CI = 33.9-45.0 pg/ml; 95% CI of differences = 2.85-17.08 pg/ml) and significantly decreased (n = 96) over the course of mAb treatment (M0.5: median = 40.4, 95% CI = 35.6-48.2 pg/ml; and M3: median = 40.9, 95% CI = 36.3-45.9 pg/ml). Absolute decrease of alpha-CGRP throughout the treatment positively correlated with the decrease in MMDs. Negative modulation of alpha-CGRP significantly associated with positive scores at the Patient Global Impression of Change scale and with analgesic overuse reversal. Beta-CGRP did not differ at baseline between patients with CM (median = 4.2, 95% CI = 3.0-4.8 pg/ml) and HCs (median = 4.4, 95% CI = 3.4-5.6 pg/ml; -1.09 to 0.60) nor was modulated by mAb treatment (n = 96; M0.5: median = 4.5, 95% CI = 3.5-5.2 pg/ml; and M3: median = 4.6, 95% CI = 3.7-5.2 pg/ml). INTERPRETATION: Treatment with mAbs, regardless of its target, is able to progressively normalize basally increased alpha-CGRP levels in CM and this effect correlates with efficacy measures, which supports a role of this neuropeptide as the first CM biomarker. ANN NEUROL 2023;94:285-294.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Gárate G, González-Quintanilla V, González A, et al. Serum Alpha and Beta-CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor. Ann Neurol. 2023. PMID: 37038806. doi:10.1002/ana.26658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。